Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Duchenne Muscular Dystrophy Drugs Global Market Report 2025
Request Sample Buy Now
Global Duchenne Muscular Dystrophy Drugs Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : June 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Duchenne Muscular Dystrophy Drugs Global Market Report 2025

By Drug Type (Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types), By Route Of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Duchenne Muscular Dystrophy Drugs Market Overview

• Duchenne Muscular Dystrophy Drugs market size has reached to $2.83 billion in 2024

• Expected to grow to $5.31 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%

• Growth Driver: Growth In Personalized Medicine Fuelling The Growth Of The Market Due To Advancements In Genomic Technologies

• Market Trend: Corticosteroids In Duchenne Muscular Dystrophy Treatment Enhancing Muscle Strength And Slowing Disease Progression

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Duchenne Muscular Dystrophy Drugs Market?

Duchenne muscular dystrophy (DMD) drugs refer to medications and therapies aimed at managing and slowing the progression of Duchenne muscular dystrophy, a genetic disorder that causes muscle weakness and degeneration. These drugs work by targeting the underlying genetic mutations, improving muscle function, and enhancing quality of life. The main aim of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in patients with Duchenne muscular dystrophy.

The main types of drugs in the Duchenne muscular dystrophy drugs market are exon skipping drugs, corticosteroids, gene therapy, and others. Exon skipping drugs refer to specialized therapies that help the body produce a functional, although shorter, version of the dystrophin protein by skipping over faulty sections of the dystrophin gene during the protein-making process. The various routes of administration include oral and injectable, and several distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies.

Duchenne Muscular Dystrophy Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Duchenne Muscular Dystrophy Drugs Market Size 2025 And Growth Rate?

The duchenne muscular dystrophy (DMD) drug market size has grown rapidly in recent years. It will grow from $2.83 billion in 2024 to $3.2 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to the rise in diagnostic capabilities, growing patient registries and data collection, surging demand, a growing pipeline of clinical-stage therapies, and growth in regulatory incentives.

What Is The Duchenne Muscular Dystrophy Drugs Market Growth Forecast?

The duchenne muscular dystrophy (DMD) drug market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to the rise in early-stage biotech entrants, growth in real-world evidence and post-marketing data, rising health expenditure, growing demand for early intervention treatments, and growth in off-label corticosteroid use. Major trends in the forecast period include surging biotech innovation, integration of digital health and wearable tech, surging interest in personalized and mutation-specific therapies, gene therapy and CRISPR advancements.

The forecast of 13.4% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Added duties on specialty phosphorodiamidate morpholino oligomers (PMOs) manufactured in Europe could elevate R&D costs for veterinary-gene-therapy trials. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Veterinary Healthcare Industry?

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are significantly impacting the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care equipment. Higher duties on imported veterinary drugs, diagnostic tools, surgical instruments, and pet care products have increased operational costs for veterinary clinics, animal hospitals, and livestock care providers, forcing them to raise service fees or absorb shrinking margins. Livestock and agricultural sectors face similar challenges, with tariffs on feed additives, vaccines, and breeding equipment driving up production costs and affecting animal health management. Additionally, retaliatory tariffs in key export markets have reduced demand for U.S.-produced veterinary products, further straining industry revenues. The sector must now prioritize local sourcing, preventive care solutions, and digital health innovations to mitigate rising costs while maintaining high standards of animal care.

How Is The Duchenne Muscular Dystrophy Drugs Market Segmented?

1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies

2) Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids

3) Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies

4) Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies

What Is Driving The Duchenne Muscular Dystrophy Drugs Market? Growth In Personalized Medicine Fuelling The Growth Of The Market Due To Advancements In Genomic Technologies

The growth in personalized medicine is expected to propel the growth of the Duchenne muscular dystrophy (DMD) drugs market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable precise identification of genetic variations and tailored treatments for individuals. Personalized medicine aids Duchenne muscular dystrophy (DMD) drugs by offering targeted therapies tailored to individual genetic profiles, making treatments more effective for patients. It enhances drug development by focusing on specific genetic mutations, improving treatment outcomes and overall patient care. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the growth in personalized medicine drives the Duchenne muscular dystrophy (DMD) drugs market.

Who Are The Major Players In The Global Duchenne Muscular Dystrophy Drugs Market?

Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc.

What Are The Key Trends Of The Global Duchenne Muscular Dystrophy Drugs Market? Corticosteroids In Duchenne Muscular Dystrophy Treatment Enhancing Muscle Strength And Slowing Disease Progression

Major companies operating in the Duchenne muscular dystrophy (DMD) drugs market are focusing on developing innovative solutions, such as corticosteroids, to improve muscle strength, slow disease progression, and enhance overall patient outcomes. Corticosteroids are a class of steroid hormones produced naturally in the adrenal glands or synthesized as medications to reduce inflammation and suppress the immune system. For instance, in March 2024, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, launched AGAMREE (vamorolone) oral suspension 40 mg/mL, a Food and Drug Administration (FDA)-approved treatment for Duchenne muscular dystrophy in patients aged two and older. AGAMREE is a corticosteroid that works by reducing inflammation and stabilizing muscle cell membranes, helping to slow disease progression.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Duchenne Muscular Dystrophy Drugs Market? Catalyst Pharmaceuticals Strengthens Duchenne Muscular Dystrophy DMD Portfolio Through Strategic Acquisition Of Vamorolone License

In July 2023, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, acquired an exclusive North American license for vamorolone (AGAMREE), a Duchenne Muscular Dystrophy (DMD) drug, from Santhera Pharmaceuticals for an undisclosed amount. With this acquisition, Catalyst Pharmaceuticals aims to expand its portfolio by offering a more effective alternative for Duchenne muscular dystrophy patients, and meet the growing demand for safer and more targeted treatments for Duchenne muscular dystrophy. Santhera Pharmaceuticals is a Switzerland-based pharmaceutical company specializing in developing innovative therapies for Duchenne muscular dystrophy.

What Is The Regional Outlook For The Global Duchenne Muscular Dystrophy Drugs Market?

North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Duchenne Muscular Dystrophy Drugs Market?

The Duchenne muscular dystrophy (DMD) drugs market consists of sales of utrophin modulators, anti-inflammatory agents and myostatin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Duchenne Muscular Dystrophy Drugs Industry?

The duchenne muscular dystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Duchenne Muscular Dystrophy Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $3.2 billion
Revenue Forecast In 2034 $5.31 billion
Growth Rate CAGR of 13.4% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The duchenne muscular dystrophy drugs market covered in this report is segmented –
1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments:
1) Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies
2) Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids
3) Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies
4) Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Duchenne Muscular Dystrophy Drugs Market Characteristics

3. Duchenne Muscular Dystrophy Drugs Market Trends And Strategies

4. Duchenne Muscular Dystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Duchenne Muscular Dystrophy Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Duchenne Muscular Dystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Duchenne Muscular Dystrophy Drugs Market Growth Rate Analysis

5.4. Global Duchenne Muscular Dystrophy Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Duchenne Muscular Dystrophy Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Duchenne Muscular Dystrophy Drugs Total Addressable Market (TAM)

6. Duchenne Muscular Dystrophy Drugs Market Segmentation

6.1. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Exon Skipping Drugs

Corticosteroids

Gene Therapy

Other Drug Types

6.2. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Injectable

6.3. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.4. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Eteplirsen

Golodirsen

Viltolarsen

Casimersen

Other Exon Skipping Therapies

6.5. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Prednisone

Deflazacort

Other Corticosteroids

6.6. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Micro-dystrophin Gene Therapy

CRISPR/Cas9-Based Gene Editing

Stem Cell-Based Gene Therapy

Other Gene Therapies

6.7. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Utrophin Modulators

Anti-Inflammatory Agents

Antisense Oligonucleotides

Myostatin Inhibitors

Other Supportive Therapies

7. Duchenne Muscular Dystrophy Drugs Market Regional And Country Analysis

7.1. Global Duchenne Muscular Dystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Duchenne Muscular Dystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

8.1. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Duchenne Muscular Dystrophy Drugs Market

9.1. China Duchenne Muscular Dystrophy Drugs Market Overview

9.2. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Duchenne Muscular Dystrophy Drugs Market

10.1. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Duchenne Muscular Dystrophy Drugs Market

11.1. Japan Duchenne Muscular Dystrophy Drugs Market Overview

11.2. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Duchenne Muscular Dystrophy Drugs Market

12.1. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Duchenne Muscular Dystrophy Drugs Market

13.1. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Duchenne Muscular Dystrophy Drugs Market

14.1. South Korea Duchenne Muscular Dystrophy Drugs Market Overview

14.2. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Duchenne Muscular Dystrophy Drugs Market

15.1. Western Europe Duchenne Muscular Dystrophy Drugs Market Overview

15.2. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Duchenne Muscular Dystrophy Drugs Market

16.1. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Duchenne Muscular Dystrophy Drugs Market

17.1. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Duchenne Muscular Dystrophy Drugs Market

18.1. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Duchenne Muscular Dystrophy Drugs Market

19.1. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Duchenne Muscular Dystrophy Drugs Market

20.1. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Duchenne Muscular Dystrophy Drugs Market

21.1. Eastern Europe Duchenne Muscular Dystrophy Drugs Market Overview

21.2. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Duchenne Muscular Dystrophy Drugs Market

22.1. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Duchenne Muscular Dystrophy Drugs Market

23.1. North America Duchenne Muscular Dystrophy Drugs Market Overview

23.2. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Duchenne Muscular Dystrophy Drugs Market

24.1. USA Duchenne Muscular Dystrophy Drugs Market Overview

24.2. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Duchenne Muscular Dystrophy Drugs Market

25.1. Canada Duchenne Muscular Dystrophy Drugs Market Overview

25.2. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Duchenne Muscular Dystrophy Drugs Market

26.1. South America Duchenne Muscular Dystrophy Drugs Market Overview

26.2. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Duchenne Muscular Dystrophy Drugs Market

27.1. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Duchenne Muscular Dystrophy Drugs Market

28.1. Middle East Duchenne Muscular Dystrophy Drugs Market Overview

28.2. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Duchenne Muscular Dystrophy Drugs Market

29.1. Africa Duchenne Muscular Dystrophy Drugs Market Overview

29.2. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape And Company Profiles

30.1. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape

30.2. Duchenne Muscular Dystrophy Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Duchenne Muscular Dystrophy Drugs Market Other Major And Innovative Companies

31.1. Eli Lilly and Company

31.2. Aurobindo Pharma Limited

31.3. Italfarmaco S.p.A

31.4. Sarepta Therapeutics Inc.

31.5. PTC Therapeutics Inc.

31.6. FibroGen Inc.

31.7. Wave Life Sciences Ltd.

31.8. Solid Biosciences Inc.

31.9. NS Pharma

31.10. Capricor Therapeutics Inc.

31.11. Santhera Pharmaceuticals

31.12. ReveraGen BioPharma

31.13. Antisense Therapeutics Limited

31.14. Catalyst Pharmaceuticals Inc.

31.15. EspeRare Foundation

32. Global Duchenne Muscular Dystrophy Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Drugs Market

34. Recent Developments In The Duchenne Muscular Dystrophy Drugs Market

35. Duchenne Muscular Dystrophy Drugs Market High Potential Countries, Segments and Strategies

35.1 Duchenne Muscular Dystrophy Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Duchenne Muscular Dystrophy Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Duchenne Muscular Dystrophy Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Duchenne Muscular Dystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Duchenne Muscular Dystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Pfizer Inc. Financial Performance
  • Table 79: Sanofi S.A. Financial Performance
  • Table 80: Bristol-Myers Squibb Financial Performance
  • Table 81: Novartis AG Financial Performance
  • Table 82: GSK plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Duchenne Muscular Dystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Duchenne Muscular Dystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Pfizer Inc. Financial Performance
  • Figure 79: Sanofi S.A. Financial Performance
  • Figure 80: Bristol-Myers Squibb Financial Performance
  • Figure 81: Novartis AG Financial Performance
  • Figure 82: GSK plc Financial Performance

Industry Forecast: Canine Atopic Dermatitis Market to Generate $4.09 Billion Revenue by 2029

Read More About Industry Forecast: Canine Atopic Dermatitis Market to Generate $4.09 Billion Revenue by 2029

Global Animal Antibiotics and Antimicrobials Market Projected to Reach $7.48 Billion by 2029 at a CAGR of 7.3%

Read More About Global Animal Antibiotics and Antimicrobials Market Projected to Reach $7.48 Billion by 2029 at a CAGR of 7.3%

$51.83 Billion Forecast for Animal Based Protein Supplements Market by 2029, Backed by Demand and Innovation

Read More About $51.83 Billion Forecast for Animal Based Protein Supplements Market by 2029, Backed by Demand and Innovation

Aquafeed Additives Market Forecast Reaching $2.43 Billion by 2029 at 6.9% CAGR

Read More About Aquafeed Additives Market Forecast Reaching $2.43 Billion by 2029 at 6.9% CAGR

Cattle Feed & Feed Additives Market Valuation Expected To Reach $84.77 Billion By 2029, Growing At A Rate Of 6.2%

Read More About Cattle Feed & Feed Additives Market Valuation Expected To Reach $84.77 Billion By 2029, Growing At A Rate Of 6.2%

Strong CAGR to Propel in the Companion Animal Arthritis Market and Beyond upto $6 Billion by 2029

Read More About Strong CAGR to Propel in the Companion Animal Arthritis Market and Beyond upto $6 Billion by 2029

Farm Animal Healthcare Market in Focus: Forecasting Growth Drivers, Scaling Potential, and Global Opportunities

Read More About Farm Animal Healthcare Market in Focus: Forecasting Growth Drivers, Scaling Potential, and Global Opportunities

Feed Binders Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Read More About Feed Binders Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Cell And Gene Therapy Market 2021 - By Product (Cell Therapy, Gene Therapy), By Application (Oncology, Neurological Disorders) And By Region, Opportunities And Strategies – Global Forecast To 2030...

View Report

Wound Closure Devices Global Market Report 2025 – By Product Type( Adhesives, Staples, Sutures, Strips, Sealants, Mechanical Wound Closure Devices ), By Wound Type( Chronic, Acute ), By End-Use( Hospital, Clinics, Trauma...

View Report

Isoprene Global Market Report 2025 – By Type( Polymer Grade, Chemical Grade), By Application( Polyisoprene (IR), Styrene-isoprene-styrene (SIS), Isobutylene-isoprene rubber (IIR), Other Applications), By End-Use( Tires, ...

View Report

Gene Editing Global Market Report 2025 – By Technology (CRISPR, TALEN, ZFN), By Application (Animal Genetic Engineering, Plant Genetic Engineering, Cell Line Engineering), By End Users (Biotechnology, Pharmaceutical, Con...

View Report

Nucleic Acid Based Gene Therapy Global Market Report 2025 – By Technology (Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies), By App...

View Report

Gene Therapy Global Market Report 2025 – By Gene Therapy Type (Germline Therapy, Somatic Cell Therapy), By Vector (Viral Vector, Non-Viral Vector), By Application (Oncology, Orphan Disease, Knee Osteoarthritis, Neurologi...

View Report

Cell and Gene Therapy Global Market Report 2025 – By Product (Cell Therapy, Gene Therapy), By Application (Oncology, Neurological Disorders, Other Applications), By End User (Hospitals, Ambulatory Surgical Centers, Cance...

View Report

Nucleic Acid Based Gene Therapy Market 2022 - By Nucleic Acid Technology (Anti-Sense and Anti-Gene Oligonucleotides, siRNA and RNA Interference, Gene Transfer Therapy, Ribozymes, Aptamers), By Application (Oncology, Musc...

View Report

Frequently Asked Questions

Duchenne muscular dystrophy (DMD) drugs refer to medications and therapies aimed at managing and slowing the progression of Duchenne muscular dystrophy, a genetic disorder that causes muscle weakness and degeneration. These drugs work by targeting the underlying genetic mutations, improving muscle function, and enhancing quality of life. The main aim of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in patients with Duchenne muscular dystrophy. For further insights on this market, request a sample here

The market major growth driver - Growth In Personalized Medicine Fuelling The Growth Of The Market Due To Advancements In Genomic Technologies. For further insights on this market, request a sample here

The duchenne muscular dystrophy drugs market size has grown rapidly in recent years. It will grow from $2.83 billion in 2024 to $3.2 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to the rise in diagnostic capabilities, growing patient registries and data collection, surging demand, a growing pipeline of clinical-stage therapies, and growth in regulatory incentives. The duchenne muscular dystrophy drugs market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to the rise in early-stage biotech entrants, growth in real-world evidence and post-marketing data, rising health expenditure, growing demand for early intervention treatments, and growth in off-label corticosteroid use. Major trends in the forecast period include surging biotech innovation, integration of digital health and wearable tech, surging interest in personalized and mutation-specific therapies, gene therapy and CRISPR advancements. For further insights on this market, request a sample here

The duchenne muscular dystrophy drugs market covered in this report is segmented –
1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments:
1) Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies
2) Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids
3) Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies
4) Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies For further insights on this market, request a sample here

North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc. . For further insights on this market, request a sample here.

Major trends in this market include Corticosteroids In Duchenne Muscular Dystrophy Treatment Enhancing Muscle Strength And Slowing Disease Progression. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Duchenne Muscular Dystrophy Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top